EUVIMEDEUVIMED entdecken
Vergleichsstudie

Comparing de novo chronic myeloid leukemia in blastic phase with Philadelphia chromosome–positive acute lymphoblastic leukemia after allogeneic hematopoietic cell transplantation

Yosuke Okada iD, Noriaki Tachi, Yutaka Shimazu iD, Makoto Murata, Satoshi Nishiwaki, Yasushi Onishi, Atsushi Jinguji, Naoyuki Uchida, Masatsugu Tanaka, Yuta Hasegawa iD, Ayumu Ito, Shinichi Kako und 12 weitere

Cancer · 2025

DOI: 10.1002/cncr.35627 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Cancer, 2025. Verfasst von Yosuke Okada und 23 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology, Jichi Medical University Saitama Medical Center, Saitama, Japan. Hauptthemen laut MEDLINE: Hematopoietic Stem Cell Transplantation, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Transplantation, Homologous. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 51 Literaturangaben. Gefördert von: Bristol-Myers Squibb, Novartis Pharma K.K..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

De novo chronic myeloid leukemia in blastic phase (CML‐BP) showing lymphoid immunophenotype mimics Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph‐positive ALL). Although upfront allogeneic hematopoietic cell transplantation (HCT) is considered in both diseases, it is not yet clear whether the transplant outcomes are also similar.

Methods

Using a registry database, the transplant outcomes between de novo CML‐BP and Ph‐positive ALL in negative‐minimal residual disease (MRD), positive MRD, and nonremission cohorts were compared, respectively. All of the included patients had received tyrosine kinase inhibitor therapy before HCT and underwent HCT between 2002 and 2021. Regarding Ph‐positive ALL, patients with p210 transcripts were excluded because there was concern that this group might include patients with de novo CML‐BP.

Results

Although most of the outcomes were comparable, in patients with positive MRD at HCT, de novo CML‐BP was significantly associated with superior disease‐free survival (DFS) (hazard ratio [HR] 0.6, p = .0032), overall survival (HR 0.66, p = .027), and a lower risk of relapse (HR 0.48, p = .0051). In subgroup analyses, BCR::ABL1 mutation status had a significant interaction with the disease ( p for interaction = .0027). De novo CML‐BP seemed to be associated with superior disease‐free survival in a BCR::ABL1 mutation‐positive cohort, whereas this association was not observed in a mutation‐negative cohort.

Conclusions

Considering previous reports that showed inferior outcomes for de novo CML‐BP compared to Ph‐positive ALL, the data suggested that allogeneic HCT could overcome the poor prognosis of de novo CML‐BP. These findings highlight the importance of distinguishing de novo CML‐BP from Ph‐positive ALL.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hematopoietic Stem Cell TransplantationPrecursor Cell Lymphoblastic Leukemia-LymphomaLeukemia, Myelogenous, Chronic, BCR-ABL PositiveTransplantation, HomologousPhiladelphia ChromosomeHumansMaleFemaleMiddle AgedAdultBlast CrisisYoung AdultNeoplasm, ResidualAgedAdolescentDisease-Free SurvivalFusion Proteins, bcr-abl

Stichwörter der Autor:innen

BCR::ABL1 kinase domain mutationPhiladelphia chromosome‐positive acute lymphoblastic leukemiaallogeneic hematopoietic cell transplantationde novo chronic myeloid leukemia in blastic phaseminimal residual disease

Substanzen

Fusion Proteins, bcr-abl

Autor:innen und Institutionen

  • Division of Hematology, Jichi Medical University Saitama Medical Center, Saitama, Japan.
  • Division of Hematology, National Defense Medical College Hospital, Saitama, Japan.
  • Department of Early Clinical Development, Kyoto University Hospital, Kyoto, Japan.
  • Department of Hematology, Shiga University of Medical Science, Otsu, Japan.
  • Department of Advanced Medicine, Nagoya University Hospital, Nagoya, Japan.
  • Department of Hematology, Tohoku University Hospital, Sendai, Japan.

ORCID-Profile: Yosuke Okada, Yutaka Shimazu, Yuta Hasegawa

Förderung

  • Bristol-Myers Squibb
  • Novartis Pharma K.K.

Zitieren

APA

Okada, Y., Tachi, N., Shimazu, Y., Murata, M., Nishiwaki, S., Onishi, Y., Jinguji, A., Uchida, N., Tanaka, M., Hasegawa, Y., Ito, A., Kako, S., Nishida, T., Onodera, K., Sawa, M., Nakamae, H., Toyosaki, M., Kanda, Y., Onizuka, M., …, & Tachibana, T. (2025). Comparing de novo chronic myeloid leukemia in blastic phase with Philadelphia chromosome–positive acute lymphoblastic leukemia after allogeneic hematopoietic cell transplantation. Cancer. https://doi.org/10.1002/cncr.35627

Vancouver

Okada Y, Tachi N, Shimazu Y, Murata M, Nishiwaki S, Onishi Y, et al. Comparing de novo chronic myeloid leukemia in blastic phase with Philadelphia chromosome–positive acute lymphoblastic leukemia after allogeneic hematopoietic cell transplantation. Cancer. 2025. doi:10.1002/cncr.35627

BibTeX
@article{Okada2025,
  author = {Okada, Yosuke and Tachi, Noriaki and Shimazu, Yutaka and Murata, Makoto and Nishiwaki, Satoshi and Onishi, Yasushi and Jinguji, Atsushi and Uchida, Naoyuki and Tanaka, Masatsugu and Hasegawa, Yuta and Ito, Ayumu and Kako, Shinichi and Nishida, Tetsuya and Onodera, Koichi and Sawa, Masashi and Nakamae, Hirohisa and Toyosaki, Masako and Kanda, Yoshinobu and Onizuka, Makoto and Fukuda, Takahiro and Ohbiki, Marie and Atsuta, Yoshiko and Arai, Yasuyuki and Tachibana, Takayoshi},
  title = {Comparing de novo chronic myeloid leukemia in blastic phase with Philadelphia chromosome–positive acute lymphoblastic leukemia after allogeneic hematopoietic cell transplantation},
  journal = {Cancer},
  year = {2025},
  doi = {10.1002/cncr.35627}
}
Kostenlos starten →